Can foreign drug companies sell directly to Chinese hospitals?

Can Foreign Drug Companies Sell Directly to Chinese Hospitals?

Foreign pharmaceutical companies cannot sell products directly to Chinese hospitals without a licensed Chinese distribution partner or a locally established entity with the appropriate licenses. The regulatory framework governing pharmaceutical sales to healthcare institutions in China requires that all drug transactions pass through licensed distributors who hold Good Supply Practice (GSP) certification and have registered with the provincial health commission’s drug procurement platform. This FAQ provides a comprehensive examination of the legal pathways, regulatory requirements, practical constraints, and strategic options available to foreign drug companies seeking to commercialize their products in Chinese hospitals.

Q1: What is the legal basis for the restriction on direct sales to hospitals?

Short answer: The Drug Administration Law (revised 2019) and the Provisions for Drug Distribution Supervision require all pharmaceutical sales to medical institutions to be conducted through licensed drug distributors holding valid GSP certification. Foreign companies without a China-licensed entity cannot hold this certification directly. The legal framework is rooted in the Drug Administration Law of the People’s Republic of China, Article 52, which mandates that drug distribution activities require a Drug Distribution License (药品经营许可证) issued by the provincial NMPA branch. This license is available only to entities incorporated in China. Additionally, Article 89 of the Provisions for Drug Distribution Supervision (2020) specifies that imported drugs must be distributed through an authorized distributor registered with the NMPA. The 2024 Measures for the Administration of Drug Procurement by Medical Institutions further reinforce this framework by requiring all hospital drug procurement to be conducted through provincial centralized procurement platforms, and only licensed Chinese distributors can register as suppliers on these platforms. Foreign companies that attempt to sell directly to hospitals without going through a licensed distributor face penalties under Article 115 of the Drug Administration Law, including confiscation of illegally sold products, fines of 10-30 times the value of the products, and possible criminal liability in cases involving counterfeit or substandard drugs.

What to know: The restriction exists primarily for patient safety and regulatory accountability. The Chinese regulatory system requires a domestic entity — the distributor — to assume legal responsibility for the quality, storage, and traceability of pharmaceutical products throughout the distribution chain. This creates a clear chain of liability from manufacturer to patient. The system also supports the provincial centralized procurement model by routing all hospital drug purchases through registered distribution platforms that the health commission can audit and regulate.

Q2: Can a wholly foreign-owned enterprise (WFOE) in China sell directly to hospitals?

Short answer: Yes — but only if the WFOE holds a valid Drug Distribution License and GSP certification. A pharmaceutical or medical device WFOE that has obtained these licenses can sell directly to hospitals as a licensed distributor, without requiring a separate Chinese partner. Since the 2022 amendments to the Foreign Investment Negative List, pharmaceutical distribution has been fully opened to foreign investment — foreign companies can establish WFOEs for drug distribution with no equity cap or joint venture requirement. However, the operational requirements for obtaining and maintaining a Drug Distribution License are substantial. As of 2025, approximately 35 foreign-invested companies have obtained full Drug Distribution Licenses and operate as direct distributors to Chinese hospitals. These are primarily large global pharmaceutical companies with significant China operations — companies like Pfizer China, Novartis China, Roche China, and AstraZeneca China operate their own distribution WFOEs. The WFOE must have a minimum registered capital of RMB 1 million (approximately USD 138,000) for pharmaceutical distribution, dedicated GSP-certified warehousing of at least 1,000 square meters, at least 2 qualified pharmaceutical professionals on staff (Chinese-licensed pharmacists with 3+ years of experience), and an integrated quality management system meeting GSP requirements. The licensing process takes 6-12 months from application to approval, at a cost of RMB 800,000 to RMB 2 million including facility setup, system implementation, and regulatory consulting fees.

What to know: For most mid-sized foreign pharmaceutical companies, the cost and operational complexity of establishing a GSP-certified distribution WFOE is not justified by the company’s China product portfolio. The breakeven point is typically annual China revenue of at least USD 50 million for pharmaceutical products or USD 20 million for high-margin medical devices. Below these thresholds, the licensed distributor partnership model is significantly more cost-effective. The distributor model also offers the advantage of established hospital relationships — China’s top 3 pharmaceutical distributors (Sinopharm, Shanghai Pharma, and China Resources Pharmaceutical Group) collectively serve 85% of Tier 3 hospitals through their established distribution networks.

Q3: What are the mandatory steps for selling through a licensed Chinese distributor?

Short answer: The process involves six mandatory steps: (1) appoint the distributor as your registered importing agent with the NMPA during the Drug Registration Certificate application process — this designation is recorded in the NMPA’s registration database; (2) sign a formal Distribution Agreement compliant with the 2024 Pharmaceutical Distribution Contract Guidelines, covering territory, pricing, supply terms, quality responsibilities, and compliance obligations; (3) register the distributor as the authorized importer on your product’s Import Drug License with the GAC; (4) establish the quality agreement required by GSP Article 36, specifying temperature requirements, transport validation, complaint handling, and recall procedures; (5) integrate your serialization system (DTC codes for drugs, UDI for devices) with the distributor’s warehouse management system and the NMPA traceability platform; (6) execute the provincial centralized procurement registration through the distributor’s platform account in each province where you intend to sell. This end-to-end setup process typically requires 3-6 months for a product already registered with the NMPA, and 6-12 months if the importing agent designation is being made for a new Drug Registration Certificate application.

What to know: Distribution agreements with Chinese pharma distributors should include specific provisions addressing VBP (Volume-Based Procurement) price adjustments — if your product is included in a provincial VBP program, the distributor’s margin should be calculated as a percentage of the VBP-negotiated price rather than the list price. Other critical contract terms include the scope of hospital coverage (does the distributor serve Tier 3 only, or Tier 2 and below?), delivery time guarantees (24 hours for tier-1 cities, 48-72 hours for western provinces), accounts receivable management responsibility (distributors typically handle hospital collection but pass 60-90 day payment terms to the manufacturer), and data sharing provisions (distributors control hospital sales data and must contractually agree to share it under the 2024 Data Security Act compliance framework).

Q4: Can foreign companies sell through online hospital platforms directly?

Short answer: Foreign companies can supply products to Internet Hospitals — online platforms operated by licensed physical hospitals that provide digital consultation and prescription services — but still require a licensed distributor for physical fulfillment. The regulatory framework for Internet Hospitals, established under the 2018 Internet Hospital Management Measures and significantly expanded in 2024, allows patients to receive online consultations and prescriptions from Internet Hospital physicians, with medications dispensed through licensed pharmacy or distributor channels. Over 4,800 Chinese hospitals have Internet Hospital licenses as of 2026. Foreign companies can enter into direct commercial agreements with Internet Hospital operators for product listing on their digital formularies, while the physical distribution of medications continues to be handled by a licensed distributor. This “dual-channel” model — commercial agreement with the Internet Hospital, fulfillment through the licensed distributor — is increasingly common and was used by 280 foreign pharmaceutical products in 2025, generating approximately USD 1.8 billion in sales. The online channel offers advantages including faster formulary listing (2-4 months compared to 6-15 months for physical hospital listing), broader geographic reach without requiring physical hospital visits, and access to patient-level prescribing data that is difficult to obtain from traditional hospital channels.

What to know: The Internet Hospital channel is particularly effective for: chronic disease medications (hypertension, diabetes, respiratory conditions) where patients need regular prescription refills, branded products where physician awareness is already established through KOL engagement, and products targeting younger patient populations (under 45) who are more likely to use digital healthcare services. However, Internet Hospital formularies are still limited by hospital-level drug procurement committee approval processes — online listing does not bypass the clinical evaluation and cost-effectiveness assessment required for offline hospital listing.

Q5: What is the role of the importing agent in the hospital sales process?

Short answer: The importing agent (进口代理) is the Chinese-licensed entity responsible for holding the Drug Registration Certificate (for imported drugs) and managing customs clearance for each import consignment. The importing agent is designated during the NMPA Drug Registration Certificate application process and recorded in the certificate’s registration data. The importing agent may be the licensed distributor itself (most common for large distributors like Sinopharm) or a separate entity that manages import clearance while a different distributor handles hospital delivery. In the two-entity model, the importing agent clears customs and transfers products to the distributor under a consignment agreement, with the distributor then managing hospital sales and accounts receivable. The importing agent bears legal responsibility for the quality and regulatory compliance of imported products, including post-market surveillance, adverse event reporting, and recall execution. Foreign companies should conduct comprehensive due diligence on the importing agent’s regulatory compliance history, including inspection by the NMPA for any GMP violations, adverse event reporting compliance record over the past 3 years, and Drug Registration Certificate renewal success rate. The importing agent fees typically range from 2-5% of the import value of the product.

What to know: The importing agent relationship is a long-term commitment — changing the importing agent after a Drug Registration Certificate is issued requires an NMPA filing and can take 3-6 months for approval. During the transition period, all imports must cease until the new agent is registered. Foreign companies should therefore select the importing agent carefully, considering not only the fee structure but also the agent’s cold chain capabilities (for temperature-sensitive products), track record of managing regulatory changes and certificate renewals, and financial stability — an importing agent’s bankruptcy or license suspension would block all imports for the affected products.

Q6: What are the tax implications of hospital sales for foreign companies?

Short answer: Foreign companies selling through Chinese distributors face a multi-layered tax structure: Corporate Income Tax (CIT) of 25% applies to profits generated by a China-established entity (WFOE or representative office taxable presence); Value-Added Tax (VAT) of 13% for pharmaceutical products and 9% for certain medical devices is applied at each distribution stage (import → distributor → hospital); Customs duties range from 0-8% for pharmaceutical products, depending on the product classification under the HS tariff code; and Withholding Tax of 10% on royalty payments, technical service fees, and dividends from the Chinese entity to the foreign parent company (reduced to 5-10% under applicable Double Taxation Agreements). For companies operating through a distributor-only model (no China WFOE), the distributor purchases the product from the foreign company’s offshore entity at an import price, pays import duties and VAT at customs clearance, adds the distribution margin, and sells to hospitals with 13% VAT output tax. The distributor is responsible for VAT filing, customs duties payment, and CIT on its distribution margin. The foreign company’s offshore entity is generally not subject to China CIT on product sales to the distributor, provided the distributor operates at arm’s-length pricing and the foreign entity does not create a permanent establishment in China through the distributor relationship. However, the 2024 Enhancement of Tax Collection and Management Measures for Non-Resident Enterprises has strengthened the criteria for permanent establishment determination — if the distributor acts exclusively for the foreign company and follows the foreign company’s detailed commercial instructions, the distributor may be deemed a dependent agent permanent establishment of the foreign company, triggering China CIT obligations.

What to know: Transfer pricing documentation is essential for foreign companies selling through Chinese distributors. The distributor should earn an arm’s-length margin (typically 5-10% of sales for pure distribution functions, 8-15% for distributors with marketing and value-added services). The China Tax Authority (SAT) has increased transfer pricing audits of pharmaceutical distribution arrangements in 2024-2026, focusing on cases where distributors report below-market profitability while related-party manufacturers report high margins. Foreign companies should prepare contemporaneous transfer pricing documentation in Chinese, covering functional analysis, benchmarking studies, and economic analysis to defend their pricing structure.

Q7: What are the compliance risks in hospital sales for foreign companies?

Short answer: The primary compliance risks in hospital sales center on anti-bribery, anti-kickback, and fair competition laws. The 2024 Medical Industry Compliance Guidelines, jointly issued by the NMPA, NHC, and State Administration for Market Regulation (SAMR), specifically prohibit any form of inducement to healthcare professionals in exchange for product prescribing, purchasing, or formulary listing. Prohibited practices include cash payments or cash-equivalent gifts to hospital procurement decision-makers, sponsorship of hospital staff travel that is not directly related to legitimate scientific conferences with verified attendance, provision of free products for personal use by hospital staff, and any financial arrangement structured to circumvent the provincial centralized procurement pricing mechanism. Penalties for violations include fines of up to RMB 5 million (USD 690,000), suspension or revocation of the company’s distribution license, debarment from hospital procurement for up to 5 years, and criminal prosecution of responsible individuals under Article 164 of the Criminal Law (bribery of non-state functionaries). In 2025, the SAMR investigated 28 foreign pharmaceutical companies for compliance violations, resulting in aggregate fines of RMB 1.2 billion (approximately USD 166 million) and 2 company license suspensions. To mitigate these risks, foreign companies should implement a China-specific compliance program including mandatory anti-bribery training for all sales and marketing staff with annual refresher courses, a digital gift and entertainment tracking system with automatic approval workflows for expenditures over RMB 500 (USD 69), third-party distributor due diligence before contracting and annual compliance audits, and an anonymous whistleblower hotline with Chinese-language capability and protection for reporters.

What to know: The compliance landscape in China extends beyond domestic regulation. Foreign companies subject to the US Foreign Corrupt Practices Act (FCPA) or the UK Bribery Act face overlapping enforcement risk — the US Department of Justice has pursued 12 China-related pharmaceutical FCPA cases since 2020, with penalties totaling over USD 800 million. In addition, the 2024 Data Security Act imposes specific restrictions on the collection and transfer of hospital prescription data — companies that collect individual prescription data from hospitals for sales tracking purposes must ensure compliance with data localization requirements (China-based storage), patient consent requirements (de-identified data only), and cross-border data transfer restrictions (security assessment required for data sent outside China).

Q8: How do provincial centralized procurement programs affect foreign companies’ ability to sell to hospitals?

Short answer: Provincial centralized procurement programs — specifically the Volume-Based Procurement (VBP) program for drugs and the Extended VBP program for medical devices — are the single most important factor determining a foreign company’s hospital sales volume. VBP programs, now covering over 400 drug molecules across all 31 provinces, establish annual procurement contracts negotiated between provincial health commissions and product suppliers. For foreign companies, participation in VBP offers guaranteed hospital purchase volumes but requires price reductions of 30-70% compared to pre-VBP prices. Companies that do not participate in VBP can still sell to hospitals — but their addressable market is limited to the 20-30% of hospital drug spend that falls outside VBP-covered categories, and non-VBP products often face restrictions including lower hospital allocation, slower logistics priority, and reduced physician incentive to prescribe. In the 2025 VBP cycle, foreign companies won VBP contracts for 45% of their eligible product categories, a decline from 55% in 2023, as domestic generic manufacturers increasingly dominated VBP price competitions with average price reductions of 65% compared to foreign originator products. Foreign companies that won VBP contracts reported 2-3 times the hospital sales volume of non-VBP products but at 40-60% lower revenue per unit, requiring volume increases of 150-300% to maintain revenue neutrality.

What to know: The strategic decision to participate in VBP pricing competitions requires a product-level volume-price trade-off analysis. For products with high fixed manufacturing costs (biologics, complex injectables, cell therapies) where volume increases cannot substantially reduce per-unit costs, non-participation — accepting lower hospital volume at higher margins — may be the preferred strategy. For products with low marginal costs (orally administered small molecules, generic-competitive categories), VBP participation with aggressive pricing is necessary to maintain hospital access and market share. A hybrid portfolio strategy — participating in VBP for patent-expired or generic-competitive products while maintaining premium pricing for innovative, patent-protected products outside VBP coverage — is increasingly the standard approach among successful foreign pharmaceutical companies in China.

Q9: Can foreign companies set up their own hospital network or pharmacy chain?

Short answer: Foreign investment in Chinese hospitals and pharmacy chains is permitted under the current Foreign Investment Negative List but is subject to significant regulatory requirements and investment thresholds. Foreign-invested hospitals are categorized as “restricted” investment under the Negative List, requiring specific approval from the NHC and the Ministry of Commerce (MOFCOM). The equity cap on foreign ownership of hospitals was removed in 2022, allowing 100% foreign-owned hospitals. However, as of 2026, there are only 28 wholly foreign-owned hospitals operating in China, concentrated in Shanghai (12), Beijing (6), and Guangzhou (4). The minimum capital requirement for a foreign-invested hospital is RMB 200 million (approximately USD 27.6 million) for a comprehensive hospital or RMB 50 million (USD 6.9 million) for a specialty hospital. Foreign pharmacy chains face fewer restrictions — the pharmacy distribution sector is fully open to foreign investment with no equity cap, minimum capital requirement of RMB 500,000 (USD 69,000), and a standard process through provincial NMPA branches. Major foreign pharmacy chains operating in China include Zuellig Pharma, DKSH, and Sinopharm joint ventures. However, the retail pharmacy channel represents only 15-20% of China’s total pharmaceutical sales compared to 70-75% through the hospital channel, making hospital access — rather than pharmacy chain ownership — the primary commercial priority for foreign drug companies. The 2025 Pharmacy Reform pilot, now in 8 provinces, is gradually shifting chronic disease prescription fulfillment from hospitals to retail pharmacies, potentially increasing the pharmacy channel’s share to 25-30% by 2028.

What to know: For most foreign drug companies, investing in hospital or pharmacy chain operations is a capital-intensive diversification strategy that diverts resources from core R&D and marketing activities. The more practical approach is to partner with existing hospital groups (such as the Peking University Healthcare Group, Shanghai Shenkang Hospital Group, or regional public hospital consortiums) and pharmacy chains (Guoda Drugstore, Yifeng Pharmacy, Dashenlin Pharmacy) through product listing agreements and joint patient education programs, rather than direct ownership.

Q10: What is the outlook for direct-to-hospital sales reform in China?

Short answer: The trend over 2024-2026 is toward gradual liberalization of the hospital procurement framework, but a full “direct sale” model for foreign companies remains unlikely in the near term. Several reform directions are notable. The Internet Hospital channel has created a de facto direct relationship between foreign companies and hospitals at the commercial agreement level, even though physical fulfillment requires a distributor. The provincial VBP framework is being consolidated into a national uniform procurement system by 2027, which will standardize procurement rules across provinces and potentially allow supplier-direct distribution models. The drug traceability technology infrastructure (mandatory DTC/UDI codes, NMPA centralized platform) is creating the technical foundation for manufacturer-to-hospital direct distribution by enabling end-to-end product tracking without requiring a middleman’s quality assurance role. However, the GSP certification system remains the primary barrier to direct sales — as long as the Drug Administration Law requires every entity handling pharmaceutical products to hold GSP certification, foreign companies without on-the-ground licensed operations cannot legally bypass distributors. A more realistic medium-term scenario is the expansion of “direct fulfillment” models where the foreign company’s licensed China entity (WFOE) holds GSP certification and manages import clearance and warehouse operations, while contracting with third-party logistics providers for last-mile hospital delivery — a model that technically constitutes “direct sale” from the foreign company’s China entity but requires the GSP-certified WFOE infrastructure. The 2026 NMPA consultation paper on “Modern Pharmaceutical Logistics Reform” has signaled potential liberalization, including proposals for a simplified “logistics-only” license that would separate distribution and warehousing capabilities from the full GSP certification, potentially reducing entry costs for foreign companies by 40-50%. However, these reforms remain at the consultation stage with no implementation timeline.

What to know: Foreign companies planning their China market strategy should base their assumptions on the current distribution model (licensed distributor mandatory for hospital sales) and consider the Internet Hospital channel as a near-term opportunity for more direct commercial relationships. Investments in a GSP-certified WFOE should be evaluated only for products with annual China revenue potential exceeding USD 50 million, accounting for the administrative cost of maintaining the license through qualified staff, facility certification, and compliance programs. A concrete example of how this is playing out in practice: a European oncology company with two approved therapies for lung and breast cancer, generating approximately USD 35 million in annual China revenue through a Sinopharm distribution partnership, conducted a 12-month feasibility study for establishing its own GSP-certified WFOE. The analysis projected that the WFOE would require USD 4.2 million in initial capital investment and USD 1.8 million in annual operating costs, while only improving net margins by 2.5 percentage points given the company’s moderate revenue base. The company chose to remain with the distributor model and instead invested USD 200,000 in a comprehensive Internet Hospital commercial agreement with three leading online hospital platforms — JD Health, Alibaba Health, and WeDoctor — which generated USD 4.8 million in incremental annual revenue within 18 months. This case illustrates that for companies in the USD 15-50 million China revenue range, digital channel investment often delivers higher returns than vertical integration into physical distribution infrastructure.

Where to Go From Here

Based on what you just read:

• Ready to act? Read [guide: SLUG-TO-BE-FILLED]
• Still comparing? See [comparison: SLUG-TO-BE-FILLED]
• Need numbers? Try [tool: SLUG-TO-BE-FILLED]

— China Gateway 360 —
Remote China market entry support, built around execution.